PLpro抑制剂作为治疗新冠肺炎的潜在疗法
PLpro Inhibitors as a Potential Treatment for COVID-19.
作者信息
Han Yu, Xu Feng
机构信息
Department of Infectious Diseases, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
出版信息
Biomedicines. 2025 Jun 10;13(6):1417. doi: 10.3390/biomedicines13061417.
Abstract
The advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus disease 2019 (COVID-19) pandemic have posed a serious threat to human health and society [...].
摘要
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的出现以及随后的2019冠状病毒病（COVID-19）大流行对人类健康和社会构成了严重威胁[...]。
相似文献
1
PLpro Inhibitors as a Potential Treatment for COVID-19.PLpro抑制剂作为治疗新冠肺炎的潜在疗法
Biomedicines. 2025 Jun 10;13(6):1417. doi: 10.3390/biomedicines13061417.
2
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.
3
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.
4
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
5
Medicinal plants with anti-SARS-CoV activity repurposing for treatment of COVID-19 infection: A systematic review and meta-analysis.具有抗SARS-CoV活性的药用植物用于治疗COVID-19感染的重新利用：一项系统评价和荟萃分析。
Acta Pharm. 2021 Dec 30;72(2):199-224. doi: 10.2478/acph-2022-0021. Print 2022 Jun 1.
6
Discovery of SARS-CoV-2 papain-like protease inhibitors through machine learning and molecular simulation approaches.通过机器学习和分子模拟方法发现严重急性呼吸综合征冠状病毒2木瓜样蛋白酶抑制剂
Drug Discov Ther. 2025 Jul 4;19(3):189-199. doi: 10.5582/ddt.2025.01034. Epub 2025 Jun 27.
7
Janus kinase inhibitors for the treatment of COVID-19.Janus 激酶抑制剂治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209. doi: 10.1002/14651858.CD015209.
8
Hyperimmune immunoglobulin for people with COVID-19.COVID-19 免疫球蛋白
Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD015167. doi: 10.1002/14651858.CD015167.pub2.
9
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
10
Impact of the COVID-19 Pandemic on Colorectal Cancer Diagnosis and Treatment: a Systematic Review.COVID-19 大流行对结直肠癌诊断和治疗的影响：系统评价。
J Gastrointest Cancer. 2023 Mar;54(1):171-187. doi: 10.1007/s12029-021-00752-5. Epub 2021 Nov 29.
引用本文的文献
1
Integrating Molecular Dynamics, Molecular Docking, and Machine Learning for Predicting SARS-CoV-2 Papain-like Protease Binders.整合分子动力学、分子对接和机器学习以预测严重急性呼吸综合征冠状病毒2（SARS-CoV-2）木瓜样蛋白酶结合物
Molecules. 2025 Jul 16;30(14):2985. doi: 10.3390/molecules30142985.
本文引用的文献
1
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19.发现口服生物利用度的 SARS-CoV-2 木瓜蛋白酶样蛋白酶抑制剂可作为 COVID-19 的潜在治疗方法。
Nat Commun. 2024 Nov 23;15(1):10169. doi: 10.1038/s41467-024-54462-0.
2
Discovery of SARS-CoV-2 papain-like protease (PL) inhibitors with efficacy in a murine infection model.发现具有在鼠类感染模型中疗效的 SARS-CoV-2 木瓜蛋白酶样蛋白酶（PL）抑制剂。
Sci Adv. 2024 Aug 30;10(35):eado4288. doi: 10.1126/sciadv.ado4288.
3
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model.设计一种具有抗 SARS-CoV-2 木瓜蛋白酶样蛋白酶活性的抑制剂，在小鼠模型中具有抗病毒疗效。
Science. 2024 Mar 29;383(6690):1434-1440. doi: 10.1126/science.adm9724. Epub 2024 Mar 28.
4
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir.严重急性呼吸综合征冠状病毒2型主要蛋白酶的自然发生突变赋予对奈玛特韦的耐药性。
ACS Cent Sci. 2023 Jul 24;9(8):1658-1669. doi: 10.1021/acscentsci.3c00538. eCollection 2023 Aug 23.
5
ISG15: its roles in SARS-CoV-2 and other viral infections.ISG15：在 SARS-CoV-2 及其他病毒感染中的作用。
Trends Microbiol. 2023 Dec;31(12):1262-1275. doi: 10.1016/j.tim.2023.07.006. Epub 2023 Aug 10.
6
Accelerating antiviral drug discovery: lessons from COVID-19.加速抗病毒药物研发：COVID-19 的经验教训。
Nat Rev Drug Discov. 2023 Jul;22(7):585-603. doi: 10.1038/s41573-023-00692-8. Epub 2023 May 12.
7
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2.强效且选择性抑制 SARS-CoV-2 的木瓜蛋白酶样蛋白酶。
Nat Commun. 2023 Mar 28;14(1):1733. doi: 10.1038/s41467-023-37254-w.
8
The WHO estimates of excess mortality associated with the COVID-19 pandemic.世界卫生组织对 COVID-19 大流行相关超额死亡人数的估计。
Nature. 2023 Jan;613(7942):130-137. doi: 10.1038/s41586-022-05522-2. Epub 2022 Dec 14.
9
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.靶向 SARS-CoV-2 木瓜蛋白酶样蛋白酶的进展与挑战。
J Med Chem. 2022 Jun 9;65(11):7561-7580. doi: 10.1021/acs.jmedchem.2c00303. Epub 2022 May 27.
10
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.免疫功能低下患者持续性 SARS-CoV-2 感染治疗过程中雷米昔韦耐药突变的从头出现：一例病例报告。
Nat Commun. 2022 Mar 17;13(1):1547. doi: 10.1038/s41467-022-29104-y.
Zotero 插件